U.S. Markets open in 1 hr 15 mins

Renalytix Plc (RNLX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
12.30-0.85 (-6.46%)
At close: 04:00PM EST
13.00 +0.70 (+5.69%)
Pre-Market: 07:22AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close13.15
Bid0.00 x 800
Ask0.00 x 800
Day's Range12.11 - 13.25
52 Week Range12.11 - 35.71
Avg. Volume116,008
Market Cap480.438M
Beta (5Y Monthly)1.38
PE Ratio (TTM)N/A
EPS (TTM)-1.04
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.00
  • GlobeNewswire

    Renalytix to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

    NEW YORK and SALT LAKE CITY, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Renalytix’s management is scheduled to participate in a fireside chat on Tuesday, February 15, 2022, at 3:30 p.m. EST. Due to the format of this virtual event the presentation will not be webcast. The company will be available f

  • Zacks

    Renalytix AI PLC Sponsored ADR (RNLX) Surges 10.4%: Is This an Indication of Further Gains?

    Renalytix AI PLC Sponsored ADR (RNLX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

  • GlobeNewswire

    Positive Study Results Published for KidneyIntelX™ in Monitoring Patient Response to New Drug Therapy

    American Journal of Nephrology data demonstrates KidneyIntelX successfully monitors patient response to SGLT2 therapy in 1,325 CANagliflozin CardioVAScular Assessment Study (CANVAS) multinational clinical trial cohort patientsNEW YORK and SALT LAKE CITY, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Renalytix (NASDAQ: RNLX) (LSE: RENX) announced the publication of positive study results for KidneyIntelX™ as a risk monitoring tool to assess impact and response to novel treatments for patients with diabetes a